Cargando…
P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430537/ http://dx.doi.org/10.1097/01.HS9.0000847120.16268.0f |
| _version_ | 1784779797880111104 |
|---|---|
| author | Yacoub, A. Borate, U. Rampal, R. Ali, H. Wang, E. Gerds, A. Hobbs, G. Kremyanskaya, M. Winton, E. O’Connell, C. Goel, S. Oh, S. Schiller, G. Assad, A. Erickson-Viitanen, S. Zhou, F. Daver, N. |
| author_facet | Yacoub, A. Borate, U. Rampal, R. Ali, H. Wang, E. Gerds, A. Hobbs, G. Kremyanskaya, M. Winton, E. O’Connell, C. Goel, S. Oh, S. Schiller, G. Assad, A. Erickson-Viitanen, S. Zhou, F. Daver, N. |
| author_sort | Yacoub, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430537 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94305372022-08-31 P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY Yacoub, A. Borate, U. Rampal, R. Ali, H. Wang, E. Gerds, A. Hobbs, G. Kremyanskaya, M. Winton, E. O’Connell, C. Goel, S. Oh, S. Schiller, G. Assad, A. Erickson-Viitanen, S. Zhou, F. Daver, N. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430537/ http://dx.doi.org/10.1097/01.HS9.0000847120.16268.0f Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Yacoub, A. Borate, U. Rampal, R. Ali, H. Wang, E. Gerds, A. Hobbs, G. Kremyanskaya, M. Winton, E. O’Connell, C. Goel, S. Oh, S. Schiller, G. Assad, A. Erickson-Viitanen, S. Zhou, F. Daver, N. P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY |
| title | P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY |
| title_full | P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY |
| title_fullStr | P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY |
| title_full_unstemmed | P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY |
| title_short | P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY |
| title_sort | p1063: efficacy and safety of parsaclisib-ruxolitinib combination therapy in myelofibrosis patients with low vs higher baseline platelet count: a subgroup analysis of data from a phase 2 study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430537/ http://dx.doi.org/10.1097/01.HS9.0000847120.16268.0f |
| work_keys_str_mv | AT yacouba p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT borateu p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT rampalr p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT alih p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT wange p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT gerdsa p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT hobbsg p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT kremyanskayam p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT wintone p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT oconnellc p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT goels p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT ohs p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT schillerg p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT assada p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT ericksonviitanens p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT zhouf p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT davern p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study |